Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumonia isolates

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Stein, Claudia ^a   Makarewicz, Oliwia ^a   Bohnert, Jürgen A ^a   Pfeifer, Yvonne ^b   Kesselmeier, Miriam ^a   Hagel, Stefan ^a   Pletz, Mathias W ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; COLISTIN; MEROPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; MINOCYCLINE; OMPK35 PORIN, KLEBSIELLA PNEUMONIAE; OMPK36 PROTEIN, KLEBSIELLA PNEUMONIAE; PORIN; THIENAMYCIN DERIVATIVE;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GENETIC ANALYSIS; GENOTYPE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OMPK35 GENE; OMPK36 GENE; PHENOTYPE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

KLEBSIELLA PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, BACTERIAL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PORINS; THIENAMYCINS;

EID: 84935446818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126479     Document Type: Article

References (37)

1. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007; 20 (3):440-58, table of contents. Epub 2007/07/17. doi: 20/3/440 [pii] doi: 10.1128/CMR.00001-07 PMID: 17630334; PubMed Central PMCID: PMC1932750.
2. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrobial agents and chemotherapy. 2001; 45(4):1151-61. Epub 2001/03/21. doi: 10.1128/AAC.45.4.1151-1161.2001 PMID: 11257029; PubMed Central PMCID: PMC90438.
3. ECDC. Annual epidemiological report 2013: Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Stockholm: European Centre for Disease Prevention and Control, 2013.
4. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America. 2009; 30(10):972-6. Epub 2009/08/29. doi: 10.1086/605922 PMID: 19712030.
5. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008; 29(12):1099-106. doi: 10.1086/592412 PMID: 18973455.
6. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerging infectious diseases. 2011; 17(10):1791-8. Epub 2011/10/18. doi: 10.3201/eid1710.110655 PMID: 22000347; PubMed Central PMCID: PMC3310682.
7. Domenech-Sanchez A, Martinez-Martinez L, Hernandez-Alles S, del Carmen Conejo M, Pascual A, Tomas JM, et al. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob Agents Chemother. 2003; 47(10):3332-5. PMID: 14506051; PubMed Central PMCID: PMC201126.
8. Garcia-Fernandez A, Miriagou V, Papagiannitsis CC, Giordano A, Venditti M, Mancini C, et al. An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob Agents Chemother. 2010; 54(10):4178-84. doi: 10.1128/AAC.01301-09 PMID: 20660683; PubMed Central PMCID: PMC2944588.
9. Novais A, Rodrigues C, Branquinho R, Antunes P, Grosso F, Boaventura L, et al. Spread of an OmpK36-modified ST15 Klebsiella pneumoniae variant during an outbreak involving multiple carbapenem-resistant Enterobacteriaceae species and clones. Eur J Clin Microbiol Infect Dis. 2012; 31 (11):3057-63. Epub 2012/06/19. doi: 10.1007/s10096-012-1665-z PMID: 22706513.
10. Poulou A, Voulgari E, Vrioni G, Koumaki V, Xidopoulos G, Chatzipantazi V, et al. Outbreak caused by an ertapenem-resistant, CTX-M-15-producing Klebsiella pneumoniae sequence type 101 clone carrying an OmpK36 porin variant. J Clin Microbiol. 2013; 51(10):3176-82. Epub 2013/07/16. doi: JCM.01244-13 [pii] doi: 10.1128/JCM.01244-13 PMID: 23850951; PubMed Central PMCID: PMC3811621.
11. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012; 56(4):2108-13. doi: 10.1128/AAC.06268-11 PMID: 22252816; PubMed Central PMCID: PMC3318350.
12. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55(7):943-50. Epub 2012/07/04. doi: 10.1093/cid/cis588 PMID: 22752516.
13. Betts JW, Phee LM, Hornsey M, Woodford N, Wareham DW. In vitro and in vivo activities of tigecyclinecolistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014; 58(6):3541-6. Epub 2014/04/02. doi: 10.1128/AAC.02449-14 PMID: 24687491; PubMed Central PMCID: PMC4068506.
14. den Hollander JG, Mouton JW, Verbrugh HA. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother. 1998; 42(4):744-8. PMID: 9559776; PubMed Central PMCID: PMC105535.
15. Lee CH, Chu C, Liu JW, Chen YS, Chiu CJ, Su LH. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. J Antimicrob Chemother. 2007; 60(2):410-3. Epub 2007/06/20. doi: 10.1093/jac/dkm215 PMID: 17576696.
16. Handzlik J, Szymanska E, Alibert S, Chevalier J, Otrebska E, Pekala E, et al. Search for new tools to combat Gram-negative resistant bacteria among amine derivatives of 5-arylidenehydantoin. Bioorg Med Chem. 2013; 21(1):135-45. Epub 2012/12/12. doi: S0968-0896(12)00882-6 [pii] doi: 10.1016/j.bmc.2012.10.053 PMID: 23218781.
17. Handzlik J, Szymanska E, Wojcik R, Dela A, Jastrzebska-Wiesek M, Karolak-Wojciechowska J, et al. Synthesis and SAR-study for novel arylpiperazine derivatives of 5-arylidenehydantoin with alpha(1)-adrenoceptor antagonistic properties. Bioorg Med Chem. 2012; 20(14):4245-57. doi: 10.1016/j.bmc. 2012.05.064 PMID: 22739084.
18. Alberti S, Rodriquez-Quinones F, Schirmer T, Rummel G, Tomas JM, Rosenbusch JP, et al. A porin from Klebsiella pneumoniae: sequence homology, three-dimensional model, and complement binding. Infect Immun. 1995; 63(3):903-10. PMID: 7868262; PubMed Central PMCID: PMC173088.
19. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, et al. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother. 2013; 57(11):5258-65. doi: 10.1128/AAC.01069-13 PMID: 23939888; PubMed Central PMCID: PMC3811244.
20. Bohnert JA, Karamian B, Nikaido H. Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. Antimicrobial agents and chemotherapy. 2010; 54 (9):3770-5. Epub 2010/07/08. doi: AAC.00620-10 [pii] doi: 10.1128/AAC.00620-10 PMID: 20606071; PubMed Central PMCID: PMC2934970.
21. Gerasimenko DV, Avdienko ID, Bannikova GE, Zueva O, Varlamov VP. [Antibacterial effects of watersoluble low-molecular-weight chitosans on different microorganisms]. Prikl Biokhim Mikrobiol. 2004; 40 (3):301-6. Epub 2004/07/31. PMID: 15283332.
22. Wang XD, Cai JC, Zhou HW, Zhang R, Chen GX. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. J Med Microbiol. 2009; 58(9):1196-202. doi: 10.1099/jmm.0.008094-0 PMID: 19528170.
23. Tsai YK, Liou CH, Fung CP, Lin JC, Siu LK. Single or in combination antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to varied susceptibility to different carbapenems. PLoS One. 2013; 8(11):e79640. Epub 2013/11/23. doi: 10.1371/journal.pone.0079640 PONE-D-13-18279 [pii]. PMID: 24265784; PubMed Central PMCID: PMC3827147.
24. Martinez-Martinez L. Extended-spectrum beta-lactamases and the permeability barrier. Clin Microbiol Infect. 2008; 14(1):82-9. Epub 2007/12/25. doi: 10.1111/j.1469-0691.2007.01860.x PMID: 18154531.
25. Garcia-Sureda L, Juan C, Domenech-Sanchez A, Alberti S. Role of Klebsiella pneumoniae LamB Porin in antimicrobial resistance. Antimicrob Agents Chemother. 2011; 55(4):1803-5. doi: 10.1128/AAC. 01441-10 PMID: 21282437; PubMed Central PMCID: PMC3067167.
26. Kaczmarek FM, Dib-Hajj F, Shang W, Gootz TD. High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe. Antimicrobial agents and chemotherapy. 2006; 50(10):3396-406. Epub 2006/09/29. doi: 50/10/3396 [pii] doi: 10.1128/AAC.00285-06 PMID: 17005822; PubMed Central PMCID: PMC1610099.
27. Hong JH, Clancy CJ, Cheng S, Shields RK, Chen L, Doi Y, et al. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother. 2013; 57 (5):2147-53. doi: 10.1128/AAC.02411-12 PMID: 23459476; PubMed Central PMCID: PMC3632930.
28. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012; 55(7):943-50. doi: 10.1093/cid/cis588 PMID: 22752516.
29. Doern GV, Brecher SM. The Clinical Predictive Value (or Lack Thereof) of the Results of In Vitro Antimicrobial Susceptibility Tests. Journal of Clinical Microbiology. 2011; 49(9 Supplement):S11-S4.: doi: 10.1128/jcm.00580-11
30. Nikaido H. Porins and specific diffusion channels in bacterial outer membranes. J Biol Chem. 1994; 269(6):3905-8. Epub 1994/02/11. PMID: 7508433.
31. Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother. 2004; 53(4):592-9. doi: 10.1093/jac/dkh125 PMID: 14985271.
32. Chen CC, Feingold DS. Locus of divalent cation inhibition of the bactericidal action of polymyxin B. Antimicrob Agents Chemother. 1972; 2(5):331-5. PMID: 4363788; PubMed Central PMCID: PMC444315.
33. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrobial agents and chemotherapy. 2009; 53(8):3430-6. doi: 10.1128/AAC.01361-08 PMID: 19433570; PubMed Central PMCID: PMC2715599.
34. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Brit J Clin Pharmaco. 2011; 72(3):381-93. doi: 10.1111/j.1365-2125.2011.03991.x. WOS:000293654400003. PMID: 21501212
35. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014; 58(4):2322-8. doi: 10.1128/AAC.02166-13 PMID: 24514083; PubMed Central PMCID: PMC4023796.
36. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014; 69 (9):2305-9. Epub 2014/05/30. doi: dku168 [pii] doi: 10.1093/jac/dku168 PMID: 24872346.
37. Watkins RR, Deresinski S. Is combination therapy for carbapenem-resistant Klebsiella pneumoniae the new standard of care? Expert Review of Anti-infective Therapy. 2015; 13(4):405-7. doi: 10.1586/14787210.2015 PMID: 25711690.